117205 ⎘
Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1) Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
Engineered CasPhi2 Nucleases
#2CRYSTALLINE FORMS
#3USE OF CONJUGATES OF MICRORNA AND CARDIAC TARGETING PEPTIDES FOR TREATING HEART FAILURE
#4PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MALIGNANT BREAST CANCER
#5O-ACETYL HOMOSERINE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCING O-ACETYL HOMOSERINE OR L-METHIONINE USING SAME
#6HDAC4-MEDIATED NEUROPROTECTION
#7IMPROVED PRODUCTION OF SECRETED PROTEINS IN YEAST CELLS
#8Compositions For and Methods of Improving Viral Vectors
#9COMPOSITIONS AND METHODS FOR MODULATING SECRETED FRIZZLED RECEPTOR PROTEIN 1 (SFRP1) GENE EXPRESSION
#10HUMAN FIBROLAMELLAR HEPATOCELLULAR CARCINOMAS (hFL-HCCS)
#11METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS
#12HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE
#13COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MULTIPLE GENES
#14MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS
#15COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS
#16METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
#17METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
#18ABHD5 AND PARTIAL HDAC4 FRAGMENTS AND VARIANTS AS A THERAPEUTIC APPROACH FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
#19METHODS FOR THE DESIGN OF NONALLOSTERIC SIRTUIN ACTIVATING COMPOUNDS
#20Engineered CRISPR-Cas9 Nucleases
#21METHODS AND COMPOSITIONS TO STIMULATE RETINAL REGENERATION
#22Methods for the design of mechanism-based sirtuin activating compounds
#23Compounds and methods for detection of enzymes that remove methyl succinyl groups from epsilon-amino lysine moieties
#24KDAC VARIANTS AND USES THEREOF
#25Engineered CRISPR-Cas9 nucleases
#26Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)
#27Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties
#28USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE
#29Methods for treatment of cancer by targeting SIRT5
#30METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
#31Human fibrolamellar hepatocellular carcinomas (hFL-HCCs)
#32Methods and compositions for modulating gene expression
#33Methods for the design of mechanism-based sirtuin activating compounds
#34ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases
#35Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties
#36Engineered CRISPR-Cas9 nucleases
#37Methods and compositions for modulating gene expression
#38Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy
#39Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
#40Nanopatterned extracellular matrices enable cell-based assays with a mass spectrometric readout
#41METHODS AND MEANS FOR INCREASING STRESS TOLERANCE AND BIOMASS IN PLANTS
#42Screening method
#43Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties
#44MIR-125A-5P AS A BIOMARKER FOR BREAST CANCER
#45NEW TREATMENT AGAINST INFLUENZA VIRUS
#46HUMAN FIBROLAMELLAR HEPATOCELLULAR CARCINOMAS (hFL-HCCS)
#47HISTONE DEACETYLASE COMPOSITIONS AND USES THEREOF
#48ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases
#49METHODS AND MEANS FOR INCREASING STRESS TOLERANCE AND BIOMASS IN PLANTS
#50HUMANIZED TRANSGENIC SINGLE NUCLEOTIDE POLYMORPHISM ANIMAL SYSTEMS
#51Combination Therapy III
#52NEW TREATMENT FOR NEURODEGENERATIVE DISEASES
#53Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
#54COMPOSITIONS AND METHODS COMPRISING SIRTUIN STIMULATORS AND NON-SIRTUIN PROTEIN DEACETYLASE INHIBITORS
#55Methods for treating obesity
#56Methods for treatment of cancer by targeting Sirt5
#57Nucleic acid encoding superoxide dismutase variants and methods of use thereof
#58TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
#59Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from ε-amino lysine moieties
#60Superoxide dismutase variants and methods of use thereof
#61Methods of inhibiting cancer cell growth with HDAC inhibitors and methods of screening for HDAC10 inhibitors
#62TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
#63Method of modulating HSF-1
#64TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1
#65METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN
#66Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof
#67USE OF COMPOUNDS ACTIVATING SIRT-3 FOR MIMICKING EXERCISE
#68HDAC REGULATION ASSAYS, COMPOUNDS AND THERAPEUTIC COMPOSITIONS
#69MARKER OF PROSTATE CANCER
#70Screening method
#71COMPOSITIONS COMPRISING HDAC INHIBITORS AND METHODS OF THEIR USE IN RESTORING STEM CELL FUNCTION AND PREVENTING HEART FAILURE
#72Methods and compositions for regulating HDAC4 activity
#73Silencing RNA molecules and their use in bone formation
#74Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain